Propensity-weighted Long-term Risk of Urinary Adverse Events After Prostate Cancer Surgery, Radiation, or Both

被引:79
作者
Jarosek, Stephanie L. [1 ]
Virnig, Beth A. [2 ]
Chu, Haitao [3 ]
Elliott, Sean P. [1 ]
机构
[1] Univ Minnesota, Sch Med, Dept Urol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA
关键词
Outcomes research; Prostate cancer; Reconstructive urology; SEER-Medicare; Urinary adverse effects; MARGINAL STRUCTURAL MODELS; DOSE-RATE BRACHYTHERAPY; SEER-MEDICARE DATA; RADICAL PROSTATECTOMY; COMPLICATIONS; RADIOTHERAPY; THERAPY; MORBIDITY; GENITOURINARY; POPULATION;
D O I
10.1016/j.eururo.2014.08.061
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate cancer is the second most common cancer in men and has high survivorship, yet little is known about the long-term risk of urinary adverse events (UAEs) after treatment. Objective: To compare the long-term UAE incidence across treatment and control groups. Design, setting, and participants: Using a matched-cohort design, we identified elderly men treated with external-beam radiotherapy (EBRT; n = 44 318), brachytherapy (BT; n = 14 259), EBRT+BT (n = 11 835), radical prostatectomy (RP; n = 26 970), RP+EBRT (n = 1557), or cryotherapy (n = 2115) for non-metastatic prostate cancer and 144 816 non-cancer control individuals from the population-based Surveillance, Epidemiology, and End Results-Medicare linked data from 1992-2007 with follow-up through 2009. Outcome measures and statistical analysis: The incidence of treated UAEs and time from cancer treatment to first UAE were analyzed in terms of propensity-weighted survival. Results: Median follow-up was 4.14 yr. At 10 yr, all treatment groups experienced higher propensity-weighted cumulative UAE incidence than the control group (16.1%; hazard risk [HR] 1.0), with the highest incidence for RP+EBRT (37.8%; HR 3.19, 95% confidence interval [CI] 2.79-3.66), followed by BT+EBRT (28.4%; HR 1.97, CI 1.85-2.10), RP (26.6%; HR 2.44, CI 2.34-2.55), cryotherapy (23.4%; HR 1.56, CI 1.30-1.87), BT (19.8%; HR 1.43, CI 1.33-1.53), and EBRT (19.7%; HR 1.11, CI 1.07-1.16). Bladder outlet obstruction was the most common event. Conclusions: Men undergoing RP, RP+EBRT, and BT+EBRT experienced the highest UAE risk at 10 yr, although UAEs accrued differently over extended follow-up. The significant background UAE rate among non-cancer control individuals yields a risk attributable to prostate cancer treatment that is 17% lower than prior estimates. Patient summary: We show that treatment for prostate cancer, especially combinations of two treatments such as radiation and surgery, carries a significant risk of urinary adverse events such as urethral stricture. This risk increases with time since treatment, emphasizing that treatments have long-term effects. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 50 条
  • [41] Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment
    Bhatnagar, V.
    Stewart, S. T.
    Huynh, V.
    Jorgensen, G.
    Kaplan, R. M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (02) : 136 - 146
  • [42] Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer
    Baskin, Avi
    Cowan, Janet E.
    Braun, Avery
    Lonergan, Peter E.
    Mohamad, Osama
    Washington III, Samuel L.
    Zhao, Shoujun
    Broering, Jeanette M.
    Cooperberg, Matthew R.
    Breyer, Benjamin N.
    Carroll, Peter R.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (10) : 429.e9 - 429.e14
  • [43] The association between age and long-term quality of life after curative treatment for prostate cancer: a cross-sectional study
    Sletten, Reidun
    Christiansen, Ola Berger
    Oldervoll, Line Merethe
    Astrom, Lennart
    Skjellegrind, Havard Kjesbu
    Benth, Jurate Saltyte
    Kirkevold, Oyvind
    Bergh, Sverre
    Gronberg, Bjorn Henning
    Rostoft, Siri
    Bye, Asta
    Mork, Paul Jarle
    Slaaen, Marit
    SCANDINAVIAN JOURNAL OF UROLOGY, 2024, 59 : 31 - 38
  • [44] Long-term outcomes of prostate cancer patients with lymph nodes metastasis after radical prostatectomy and pelvic lymph node dissection
    De Vergie, S.
    Gaschignard, N.
    Baron, M.
    Branchereau, J.
    Luyckx, F.
    Butel, T.
    Perrouin-Verbe, M. -A.
    Bouchot, O.
    Rigaud, J.
    PROGRES EN UROLOGIE, 2018, 28 (01): : 25 - 31
  • [45] Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up
    Kaulanjan, Kevin
    Lavigne, Danny
    Saad, Fred
    Karakiewicz, Pierre, I
    Flammia, Rocco Simone
    Kluth, Luis Alex
    Mandel, Philipp
    Chun, Felix K-H
    Taussky, Daniel
    Hoeh, Benedikt
    CANCERS, 2022, 14 (15)
  • [46] Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy
    Bao, Alicia
    Barsky, Andrew R.
    Maxwell, Russell
    Bekelman, Justin E.
    Both, Stefan
    Christodouleas, John P.
    Deville, Curtiland
    Fang, Penny
    Tochner, Zelig A.
    Vapiwala, Neha
    INTERNATIONAL JOURNAL OF PARTICLE THERAPY, 2022, 8 (04) : 14 - 24
  • [47] Radiation Dose to the Penile Structures and Patient-Reported Sexual Dysfunction in Long-Term Prostate Cancer Survivors
    Thor, Maria
    Olsson, Caroline E.
    Oh, Jung Hun
    Alsadius, David
    Pettersson, Niclas
    Deasy, Joseph O.
    Steineck, Gunnar
    JOURNAL OF SEXUAL MEDICINE, 2015, 12 (12) : 2388 - 2397
  • [48] Long-term Risk of Reoperation After Synthetic Mesh Midurethral Sling Surgery for Stress Urinary Incontinence
    Berger, Alexander A.
    Tan-Kim, Jasmine
    Menefee, Shawn A.
    OBSTETRICS AND GYNECOLOGY, 2019, 134 (05) : 1047 - 1055
  • [49] The Significance of Prostate Specific Antigen Persistence in Prostate Cancer Risk Groups on Long-Term Oncological Outcomes
    Milonas, Daimantas
    Venclovas, Zilvinas
    Sasnauskas, Gustas
    Ruzgas, Tomas
    CANCERS, 2021, 13 (10)
  • [50] Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
    Tsumura, Hideyasu
    Satoh, Takefumi
    Ishiyama, Hiromichi
    Tabata, Ken-ichi
    Komori, Shouko
    Sekiguchi, Akane
    Ikeda, Masaomi
    Kurosaka, Shinji
    Fujita, Tetsuo
    Kitano, Masashi
    Hayakawa, Kazushige
    Iwamuro, Masatsugu
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (02) : 95 - 103